UGROCAP — Deck

Ugro Capital Ltd · UGROCAP · NSE/BSE

A 7-year-old MSME NBFC trading at 0.59x book mid-pivot — turnaround or value trap?

₹94
CMP
₹1,456 Cr
Market Cap
0.59x
Price / Book
8.3%
ROE (FY25)
Down 52% from 52-week high of ₹196, strategic pivot announced Q3 FY26, promoter holds just 1.7%
1 · Business

MSME lender pivoting from co-lending to branch-based secured LAP

  • Emerging Market LAP (21% of AUM). 300+ branches in tier 2/3 towns, 18.6% yield, ₹18L avg ticket — now the core growth engine replacing DSA-led channels.
  • Embedded Finance / MSL (12% of AUM). Digital micro-lending at 26% yield via PhonePe, Airtel, Meesho partnerships — scaling fast from ₹1,270 Cr AUM.
  • Prime Intermediated (41% of AUM). Low-yield DSA-led book at ~14% being deliberately wound down with ₹220 Cr of annualized cost cuts announced.
No durable moat yet. GRO Score underwriting is unproven at scale through a credit cycle.
2 · Numbers

Revenue up 9x in 4 years, but ROE has never crossed cost of equity

8.3%
ROE (needs 12%+ to rerate)
0.59x
P/Book (peers at 1.8-2.8x)
2.2%
GNPA (was 2.5% in Q1 FY26)
-52%
From 52w High (₹196 → ₹94)

AUM grew 40% YoY to ₹15,454 Cr but Q3 FY26 standalone PAT collapsed from ₹43 Cr to ₹6 Cr as co-lending income shifted to Profectus. The transition from upfront gains to annuity NII will temporarily depress earnings.

3 · People

Grade B — capable founder, dangerously low skin in the game

  • Shachindra Nath (Vice Chairman & MD). Ex-Religare Group CEO. Built ₹15,000 Cr AUM from scratch in 7 years. Holds just 1.7% — down from 2.9% in FY23.
  • Serial dilution. ₹3,100+ Cr raised since 2018 against a ₹1,456 Cr market cap — every equity investor is underwater on mark-to-market basis.
  • Board strength. Former SEBI WTM, ex-CMD Indian Overseas Bank, ex-MD LIC. But 3 of 10 seats held by PE nominee directors with exit-driven timelines.
  • Credibility gap. Promised no capital needed for 2 years in May 2024, then raised ₹1,292 Cr within 12 months. Every ROA target has been deferred.
4 · Story

From DataTech disruptor to branch-based secured lender in 3 acts

Act 1 (FY19-FY24): Build & Scale. Acquired a shell company, raised ₹1,000 Cr from PE, built GRO Score underwriting and co-lending partnerships. AUM compounded 60%+ annually. Management guided 4% ROA, 18% ROE, ₹20,000 Cr AUM by FY25. Stock peaked at ₹295.

Act 2 (FY25-Now): Reality & Pivot. ROA stalled at 2.3%, co-lending income proved volatile, and the stock collapsed 68% from peak. Q3 FY26 brought a fundamental strategic realignment: DSA verticals wound down, ₹220 Cr cost cut, Profectus acquired for ₹1,400 Cr. The narrative shifted from platform scale to annuity earnings quality.

The pivot is an honest admission that the multi-channel model was not generating sustainable profitability.
5 · Risks

Three risks that could break the thesis

  • MSME credit cycle. The loan book has never been stress-tested at ₹15,000+ Cr scale. GNPA guided to 2.7-3.0% as the book seasons — a downturn could push it past 3.5%, eroding book value itself.
  • Profectus integration. ₹1,400 Cr acquisition must deliver ₹150 Cr annualized profit accretion. Young NBFCs have a poor track record with M&A. If acquired book GNPA rises above 2.5%, the deal turns value-destructive.
  • Capital exhaustion. CRAR at 19.4% looks adequate, but management has broken every capital-sufficiency promise. Another dilutive raise below book would confirm a structural inability to self-fund growth.
6 · Verdict

CONDITIONAL BUY · 38% upside to ₹130, but only as a 2-3% starter position

COND. BUY
Recommendation
₹130
Prob-Weighted Value
+38%
Upside
2-3%
Position Size

Watchlist to re-rate: ROE crossing 12% by Q2 FY27, Profectus delivering ₹100+ Cr annualized profit, no further dilutive raise below book